Literature DB >> 17269442

Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons.

Kirstin J Beggs1, Alex Lyubimov, Jade N Borneman, Amelia Bartholomew, Annemarie Moseley, Robert Dodds, Michael P Archambault, Alan K Smith, Kevin R McIntosh.   

Abstract

Mesenchymal stem cells (MSCs) express low immunogenicity and demonstrate immunomodulatory properties in vitro that may safely allow their transplantation into unrelated immunocompetent recipients without the use of pharmacologic immunosuppression. To test this hypothesis, three groups of baboons (three animals per group) were injected as follows: group 1 animals were injected with vehicle; group 2 animals were injected IV with DiI-labeled MSCs (5 x 106 MSCs/kg body weight) followed 6 weeks later by IM injections of DiO-labeled MSCs (5 x 10(6) MSCs/kg) from the same donor; and group 3 animals were treated similarly as group 2 except that MSCs were derived from two different donors. Muscle biopsies, performed 4 weeks after the second injection of MSCs, showed persistence of DiO-labeled MSCs in 50% of the recipients. Blood was drawn at intervals for evaluation of basic immune parameters (Con A mitogen responsiveness, PBMC phenotyping, immunoglobulin levels), and to determine T-cell and alloantibody responses to donor alloantigens. Host T-cell responses to donor alloantigens were decreased in the majority of recipients without suppressing the overall T-cell response to Con A, or affecting basic parameters of the immune system. All recipient baboons produced alloantibodies that reacted with donor PBMCs. Two of six animals produced alloantibodies that reacted with MSCs. We conclude that multiple administrations of high doses of allogeneic MSCs affected alloreactive immune responses without compromising the overall immune system of recipient baboons. The induction of host T-cell hyporesponsiveness to donor alloantigens may facilitate MSC survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17269442     DOI: 10.3727/000000006783981503

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  57 in total

Review 1.  Mesenchymal stromal cells in renal transplantation: opportunities and challenges.

Authors:  Federica Casiraghi; Norberto Perico; Monica Cortinovis; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2016-02-08       Impact factor: 28.314

2.  Translational development of mesenchymal stem cell therapy for cardiovascular diseases.

Authors:  Joshua M Hare
Journal:  Tex Heart Inst J       Date:  2009

3.  Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells.

Authors:  Merced Leiker; Gen Suzuki; Vijay S Iyer; John M Canty; Techung Lee
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

Review 4.  Immunomodulation by mesenchymal stem cells in veterinary species.

Authors:  Danielle D Carrade; Dori L Borjesson
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

5.  HSCT recipients have specific tolerance to MSC but not to the MSC donor.

Authors:  Mikael Sundin; A John Barrett; Olle Ringdén; Mehmet Uzunel; Helena Lönnies; Asa-Lena Dackland; Birger Christensson; Katarina Le Blanc
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

6.  Expression of blood group genes by mesenchymal stem cells.

Authors:  Richard Schäfer; Martina Schnaidt; Roland A Klaffschenkel; Georg Siegel; Michael Schüle; Maria Anna Rädlein; Ursula Hermanutz-Klein; Miriam Ayturan; Marine Buadze; Christoph Gassner; Lusine Danielyan; Torsten Kluba; Hinnak Northoff; Willy A Flegel
Journal:  Br J Haematol       Date:  2011-03-21       Impact factor: 6.998

Review 7.  Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: a comprehensive review.

Authors:  Jan Voswinkel; Sabine Francois; Jean-Marc Simon; Marc Benderitter; Norbert-Claude Gorin; Mohamad Mohty; Loïc Fouillard; Alain Chapel
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

8.  [Mesenchymal stem cells and rheumatism. State of the art].

Authors:  J Voswinkel; A Chapel
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

9.  Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().

Authors:  Danielle D Carrade; Michael W Lame; Michael S Kent; Kaitlin C Clark; Naomi J Walker; Dori L Borjesson
Journal:  Cell Med       Date:  2012-01-01

10.  Intra-brain microinjection of human mesenchymal stem cells decreases allodynia in neuropathic mice.

Authors:  Dario Siniscalco; Catia Giordano; Umberto Galderisi; Livio Luongo; Nicola Alessio; Giovanni Di Bernardo; Vito de Novellis; Francesco Rossi; Sabatino Maione
Journal:  Cell Mol Life Sci       Date:  2009-11-24       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.